NEW YORK (GenomeWeb News) – Promega today announced that it has partnered with SignalChem Pharmaceuticals to offer a combination of their technologies for profiling kinase inhibitors against the human kinome.
The offering will combine SignalChem's Kinase Enzyme Systems with Promega's ADP-Glo Kinase Assay. Madison, Wis.-based Promega said that the combination provides "all of the necessary tools and give[s] drug screeners unprecedented ease to profile inhibitors against the human kinome for off-target effects."
Promega said that its will distribute SignalChem's Kinase Enzyme Systems as a stand-alone enzyme system or in combination with its own ADP-Glo Assay.
Further terms of the alliance were not disclosed.